Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.

Translational lung cancer research·2026

Same author

Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma.

Translational lung cancer research·2026

Same author

Staging of non-metastatic nasopharyngeal carcinoma with PET/CT.

European radiology·2026

Same author

Management of Oligoprogression in the Thorax-Are We Making This Too Complicated?

International journal of radiation oncology, biology, physics·2026

Same author

Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions.

Veterinary and comparative oncology·2026

Same author

Open vs. Laparoscopic Surgery for Rectal Cancer: Impact on Identification and Preservation of Pelvic Autonomic Nerves and Effects on Urinary and Sexual Function and Quality of Life.

Journal of clinical medicine·2026

Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 5, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.

Chrysalyne D Schmults¹, Rachel Blitzblau², Sumaira Z Aasi³

¹Dana-Farber/Brigham and Women's Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN

|January 20, 2024

Summary

This summary is machine-generated.

The National Comprehensive Cancer Network (NCCN) updated Merkel cell carcinoma (MCC) guidelines, introducing new criteria for locally advanced disease and clarifying treatment options. These updates enhance diagnostic and therapeutic strategies for MCC patients.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Merkel Cell Polyomavirus Infection and Detection

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

Related Experiment Videos

Last Updated: Jul 5, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Merkel Cell Polyomavirus Infection and Detection

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

Area of Science:

Oncology
Dermatology
Medical Guidelines

Background:

Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer.
Current NCCN Guidelines require annual updates to reflect the latest research and clinical insights.
Expert review and external submissions inform guideline revisions.

Purpose of the Study:

To detail recent updates to the NCCN Guidelines for Merkel cell carcinoma (MCC).
To introduce a new algorithmic page for "Clinical N0 Disease, Locally Advanced MCC."
To clarify definitions and management strategies for locally advanced and in-transit MCC.

Main Methods:

Annual review and revision process by the NCCN panel.
Incorporation of expert feedback and external submissions.
Development of new guideline content and updates to existing sections.

Main Results:

Introduction of a new section for "Clinical N0 Disease, Locally Advanced MCC."
Clarification of the term "nonsurgical" in the context of locally advanced MCC.
Inclusion of updated management for in-transit disease and systemic therapy options.

Conclusions:

The updated NCCN Guidelines provide refined recommendations for diagnosing and treating MCC.
The new guidance addresses specific challenges in managing locally advanced and in-transit MCC.
These revisions aim to optimize patient care through evidence-based strategies.